Core Viewpoint - Zhongsheng Pharmaceutical's stock price has experienced a decline, and the company is planning a share reduction by its financial director while also projecting significant profit growth for the first half of 2025 [1] Company Summary - As of August 6, 2025, Zhongsheng Pharmaceutical's stock price is reported at 20.05 yuan, down 0.75 yuan or 3.61% from the previous trading day [1] - The company operates in the pharmaceutical manufacturing industry, specifically within the traditional Chinese medicine sector, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, raw materials, and health products [1] - Zhongsheng Pharmaceutical has a diverse product line that addresses various therapeutic areas, including cardiovascular, respiratory, and digestive systems [1] Financial Summary - The company announced that its Vice President and CFO, Long Chunhua, plans to reduce holdings by up to 900,000 shares within the next three months, which is estimated to be around 18 million yuan based on the current stock price [1] - A performance forecast released on July 15 indicates that the net profit for the first half of 2025 is expected to be between 170 million yuan and 210 million yuan, representing a year-on-year growth of 94.49% to 140.25% [1] - On August 6, the net outflow of main funds for Zhongsheng Pharmaceutical was 149.61 million yuan, accounting for 0.98% of the circulating market value, while the cumulative net inflow over the past five trading days was 282.37 million yuan, representing 1.85% of the circulating market value [1]
众生药业股价下跌3.61% 财务总监拟减持90万股